TNFRSF14编码蛋白是肿瘤坏死因子受体超家族14，其调节先天免疫和获得性免疫中的多种生理和病理反应。它在多种类型的细胞上表达，包括T细胞、B细胞、NK细胞、树突状细胞和髓细胞，以及非淋巴器官，包括肺、肝和肾。TNFRSF14是一种肿瘤抑制因子和免疫原性调节因子，能够根据其结合的特定配体向T细胞发送刺激性和抑制性信号。TNFRSF14的突变在弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤（FL）中发现。在42%的经典霍奇金淋巴瘤（CHL）病例中观察到含有TNFRSF14的区域的重复拷贝数丢失。TNFRSF14表达在大肠癌、肝细胞癌和食管鳞状细胞癌中缺失。

TNFRSF14 encodes the tumor necrosis factor receptor superfamily 14, also known as Herpesvirus entry mediator (HVEM). It is expressed on several types of cells, including T cells, B cells, NK cells, dendritic cells, and myeloid cells, as well as non-lymphoid organs including lung, liver and kidney. TNFRSF14 is a tumor suppressor and immunogenicity regulation factor and is capable of sending both stimulatory and inhibitory signals to T cells depending on the particular ligand it binds. Mutations in TNFRSF14 has been demonstrated in the pathogenesis of both diffuse large B-cell lymphoma and follicular lymphoma (FL). These mutations are associated with high-risk clinical features, and patients with a mutation in TNFRSF14 responded poorly to rituximab. Recurrent copy number loss of the region containing TNFRSF14 was observed in 42% of the cases with classical Hodgkin lymphoma (CHL). Finally, TNFRSF14 expression is deregulated in colorectal cancer, hepatocellular carcinoma and esophageal squamous cell carcinoma.

GeneCards OncoKB My Cancer Genome